Celliaz selects Andelyn to develop and manufacture retinal gene therapy
Image: Primary Andelyn Biosciences and Celliaz announced a partnership to develop and manufacture CLZ002, an investigational gene therapy for retinitis pigmentosa. Andelyn will provide plasmid and AAV2 viral-vector manufacturing through its Curator Suspension Platform, supporting studies needed for an investigational new drug application and a planned Phase 1/2 trial.
Celliaz says the therapy aims to restore retinal regeneration by preventing the protein PROX1 from transferring into Müller glia, retinal cells with latent regenerative potential. The approach targets a regeneration mechanism rather than individual disease-causing mutations; clinical testing remains planned.
Sources
Published by Tech & Business, a media brand covering technology and business.
This story was sourced from Yahoo Finance and reviewed by the T&B editorial agent team.
Back to Newswire
